TG Therapeutics Secures $500 Million Credit Facility to Fuel BRIUMVI Growth and Pipeline Development
Key Insights
TG Therapeutics (search) secured a new five-year, $750 million senior secured credit facility with Blue Owl Capital (search), providing a net $500 million in non-dilutive capital after repaying existing debt.
The company expanded its share repurchase program from $100 million to $300 million, having already repurchased $38 million of common stock at an average price of $28.98 per share.
The financing will support continued commercial growth of BRIUMVI, a glycoengineered monoclonal antibody approved for relapsing multiple sclerosis (search) treatment in the U.S. and internationally.
TG Therapeutics (search) announced on March 19, 2026, that it has secured a new five-year, $750 million senior secured credit facility with funds managed by Blue Owl Capital (search), resulting in a net raise of $500 million in non-dilutive capital after repaying its existing $250 million facility. The new facility includes provisions for up to an additional $250 million of incremental capital, bringing the total potential facility size to $1 billion.
Enhanced Financial Position Supports Strategic Growth
Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics (search), stated that the expanded credit facility "significantly enhances our financial position with increased scale and improved terms compared to our prior facility." The financing builds on the company's cash flow positive business and provides substantial non-dilutive capital to support opportunistic share repurchases, business development, and continued investment in BRIUMVI growth and pipeline advancement.
In connection with the new facility, TG Therapeutics (search)' Board of Directors authorized an increase to its share repurchase program from $100 million to $300 million. As of March 18, 2026, the company has repurchased approximately $38 million of common stock under its existing program at an average price of $28.98 per share.
BRIUMVI Commercial Success Drives Investor Confidence
The financing reflects strong commercial execution with BRIUMVI, TG Therapeutics (search)' novel monoclonal antibody for relapsing multiple sclerosis (search) (RMS). Sandip Agarwala, Managing Director and Head of Life Sciences at Blue Owl, noted that "TG Therapeutics continues to demonstrate strong commercial execution with BRIUMVI and a disciplined approach to growth."
BRIUMVI (ublituximab-xiiy) is a glycoengineered monoclonal antibody that targets a unique epitope on CD20 (search)-expressing B-cells (search). The drug is uniquely designed to lack certain sugar molecules normally expressed on antibodies, a process called glycoengineering that allows for efficient B-cell depletion at low doses.
Regulatory Approvals and Market Position
BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The drug has also received approval from several regulatory agencies outside the U.S. for treating adult patients with RMS who have active disease defined by clinical or imaging features.
Clinical Safety Profile and Monitoring Requirements
In MS clinical trials, BRIUMVI demonstrated a manageable safety profile with specific monitoring requirements. The incidence of infusion reactions in BRIUMVI-treated patients who received infusion reaction-limiting premedication prior to each infusion was 48%, with the highest incidence within 24 hours of the first infusion. Serious infusion reactions occurred in 0.6% of BRIUMVI-treated patients, with some requiring hospitalization.
The overall rate of infections in BRIUMVI-treated patients was 56% compared to 54% in teriflunomide-treated patients, with serious infections occurring at a rate of 5% compared to 3% respectively. There were 3 infection-related deaths in BRIUMVI-treated patients. The most common infections included upper respiratory tract infection (45%) and urinary tract infection (10%).
Multiple Sclerosis Market Opportunity
Relapsing multiple sclerosis (search) represents a significant market opportunity, with nearly 1 million people living with MS in the United States and approximately 85% initially diagnosed with relapsing-remitting multiple sclerosis (search) (RRMS). Worldwide, more than 2.3 million people have a diagnosis of MS. RRMS is characterized by episodes of new or worsening signs or symptoms followed by periods of recovery, with the majority of patients eventually transitioning to secondary progressive multiple sclerosis (search).
Company Focus and Pipeline Development
TG Therapeutics (search) is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Beyond BRIUMVI, the company maintains a research pipeline that will benefit from the additional capital provided by the new credit facility.
The expanded financial resources position TG Therapeutics (search) to continue investing in BRIUMVI's commercial growth while advancing its broader pipeline of B-cell targeted therapies, supporting the company's strategic initiatives in the competitive multiple sclerosis (search) treatment landscape.